Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors

Zacks04-16

Shares of cancer-biotech Janux Therapeutics, Inc. JANX have surged close to 50% in the past week, following a report issued by Bloomberg. The report stated that the company is considering a potential ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2427880072?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e","is_english":true,"pubTime":"2024-04-16 00:54","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2427880072","market":"us","top_or_hot":-1,"title":"Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors","media":"Zacks","content":"<div>\n<p>Shares of cancer-biotech Janux Therapeutics, Inc. JANX have surged close to 50% in the past week, following a report issued by Bloomberg. The report stated that the company is considering a potential ...</p>\n\n<a href=\"https://finance.yahoo.com/news/janux-janx-rises-almost-50-165400956.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJanux (JANX) Rises Almost 50% in a Week on Buyout Rumors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-16 00:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/janux-janx-rises-almost-50-165400956.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of cancer-biotech Janux Therapeutics, Inc. JANX have surged close to 50% in the past week, following a report issued by Bloomberg. The report stated that the company is considering a potential ...</p>\n\n<a href=\"https://finance.yahoo.com/news/janux-janx-rises-almost-50-165400956.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANIP","symbol_name":"ANI Pharmaceuticals, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/janux-janx-rises-almost-50-165400956.html","article_id":"2427880072","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2427880072","pubTimestamp":1713200040,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Shares of cancer-biotech Janux Therapeutics, Inc. JANX have surged close to 50% in the past week, following a report issued by Bloomberg. The report stated that the company is considering a potential sale after big pharmaceutical companies showed takeover interest.Per the report, JANX is currently evaluating its alternative for the buyout with a financial adviser. Apparently, Janux’s innovative pipeline of cancer candidates is attracting buyout offers from big pharma companies.Shares of Janux have rallied 49.9% in the past week against the industry’s decline of 1.8%.Janux’s portfolio currently comprises two early-stage pipeline candidates, JANX007 and JANX008, which are being developed for treating various cancer indications with novel mechanisms of action.JANX007, a tumor-activated T-cell engager that targets PSMA, is being evaluated in a phase I study for treating adult patients with metastatic castration-resistant prostate cancer .ADMA’s earnings beat estimates in three of the trail","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ANIP":"ANI Pharmaceuticals, Inc.","JANX":"Janux Therapeutics, Inc.","BK4007":"制药","LGND":"Ligand Pharmaceuticals Inc.","BK4139":"生物科技","BK4539":"次新股","ADMA":"ADMA Biologics Inc"},"translate_title":"Janux（JANX）因收购传闻在一周内上涨近50%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADMA":1,"ANIP":1,"JANX":1,"LGND":1},"content_text":"Shares of cancer-biotech Janux Therapeutics, Inc. JANX have surged close to 50% in the past week, following a report issued by Bloomberg. The report stated that the company is considering a potential sale after big pharmaceutical companies showed takeover interest.\nPer the report, JANX is currently evaluating its alternative for the buyout with a financial adviser. Apparently, Janux’s innovative pipeline of cancer candidates is attracting buyout offers from big pharma companies.\nShares of Janux have rallied 49.9% in the past week against the industry’s decline of 1.8%.\nImage Source: Zacks Investment Research\nJanux’s portfolio currently comprises two early-stage pipeline candidates, JANX007 and JANX008, which are being developed for treating various cancer indications with novel mechanisms of action.\nJANX007, a tumor-activated T-cell engager that targets PSMA, is being evaluated in a phase I study for treating adult patients with metastatic castration-resistant prostate cancer (mCRPC).\nMeanwhile, JANX008, a tumor-activated immunomodulator, is currently being investigated in a phase I study for the treatment of multiple solid tumor cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer and renal cell carcinoma.\nIn February 2024, JANX announced positive data from the ongoing studies on both its pipeline candidates. The updated data showed encouraging efficacy and a favorable safety profile with JANX007 in heavily pretreated subjects with late-stage mCRPC. The interim data display differentiated safety and encouraging signs of efficacy with JANX008 in heavily pretreated subjects with different solid tumor types.\nIt can be inferred that the early promising data for JANX007 and JANX008 can be a catalyst for the potential buyout of Janux by big pharma companies, as they remain optimistic that the respective candidates will hold their potential in late-stage studies, too.\nGiven the promising prospect that lies with JANX007 and JANX008, Janux becomes an ideal acquisition target for large-cap pharma companies who are looking to explore opportunities to expand their pipeline particularly in the treatment of cancer.\n\nJanux Therapeutics, Inc. Price\n  \nJanux Therapeutics, Inc. price | Janux Therapeutics, Inc. Quote\n\nZacks Rank & Stocks to Consider\nJanux currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the healthcare sector are ADMA Biologics, Inc. ADMA, Ligand Pharmaceuticals Incorporated LGND and ANI Pharmaceuticals, Inc. ANIP, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, estimates for ADMA Biologics’ 2024 earnings per share have improved from 22 cents to 30 cents. Year to date, shares of ADMA have rallied 33.2%.\nADMA’s earnings beat estimates in three of the trailing four quarters and met the same once, the average surprise being 85.00%.\nIn the past 60 days, estimates for Ligand’s 2024 earnings per share have improved from $4.42 to $4.56. Year to date, shares of LGND have gained 13.9%.\nEarnings of LGND beat estimates in each of the trailing four quarters, the average surprise being 84.81%.\nIn the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share have improved from $4.06 to $4.43. Year to date, shares of ANIP have jumped 21.3%.\nEarnings of ANIP beat estimates in each of the trailing four quarters, the average surprise being 109.06%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nLigand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report\nANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report\nADMA Biologics Inc (ADMA) : Free Stock Analysis Report\nJanux Therapeutics, Inc. (JANX) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2427880072"}